AKT1 and melanoma: A recent investigation has demonstrated that Evodiamine, functioning as a multi-targeted antiproliferative agent, selectively targets and suppresses the IRS4 as well as the downstream PI3K/AKT signaling cascade in vemurafenib-resistant melanoma cells.